Feb 24 (Reuters) - Kiniksa Pharmaceuticals Q4 net income USD 14.199 million.
Q4 product revenue USD 202.127 million
Q4 operating expenses USD 182.359 million
Q4 pretax profit USD 23.269 million
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments